Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer
DOI: 10.1055/s-0044-1787063
Original Article

Spectrum of Resistance Mechanisms to ALK TKIs in NSCLC: Largest Single-Center Experience from India

Ullas Batra 
1   Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India
,
Shrinidhi Nathany
2   Department of Molecular Diagnostics, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India
,
Mansi Sharma
1   Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India
,
Amrith B. P. 
1   Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India
,
Shriya Vaidya
1   Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India
,
Sakshi Mattoo
2   Department of Molecular Diagnostics, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India
,
Dushyant Kumar
2   Department of Molecular Diagnostics, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India
,
Anurag Mehta
3   Laboratory Services, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction Anaplastic lymphoma kinase (ALK) rearranged non-small cell lung carcinoma (NSCLC) has emerged as a distinct entity with growing number of potent ALK tyrosine kinase inhibitors (TKIs). Despite showing durable responses and promising survival rates, resistance to these ensue. This is the largest series of repeat biopsies from patients of ALK-positive NSCLC progressing on ALK-directed therapy from this part of the world. Using a combinatorial approach of genomics and histology, we describe the spectrum of various resistance mechanisms encountered.

Methods This is a cross-sectional study recruiting ALK-positive NSCLC cases who have progressed on any line ALK TKI and have undergone repeated biopsies followed by genomic sequencing by next-generation sequencing (NGS).

Results Thirty-two ALK-positive NSCLC patients progressed on TKI were enrolled. Median age was 53 years (range: 36–75 years) with a male predilection (male:female 1.3:1). Twenty-seven (84.4%) cases harbored an additional resistance mechanism. Eighteen of these harbored an on-target ALK alteration, with L1196M gatekeeper mutation being the most common, in 11 cases, and G1202 alteration in 3 cases. In 9 cases an off-target alteration was detected, the most frequent being TP53 mutation in 8 cases, KRAS mutation in 4 cases and MET amplification in 3 cases. Four patients underwent sequential NGS testing and allele frequency changes in ALK fusion and resistance mechanisms were demonstrated. Sixteen patients have been offered lorlatinib therapy, the median progression-free survival of which has not yet been reached.

Conclusion This is the largest series depicting ALK resistance mechanisms from a single center to date. The SPACEWALK study which demonstrated ALK TKI resistance mechanisms using plasma-based genotyping was a multicentric study. The spectrum encountered in this study is distinct from the rest of the world, thus highlighting heterogeneity within ALK-rearranged tumors. Comprehensive clinical evaluation at disease progression coupled with NGS-based genotyping will pave the way for lucid understanding of disease biology, thus aiding in the institution of optimal therapy.

Keywords

ALK - resistance - liquid biopsy - NGS

Publication/Presentation Statement

This study has been presented at the European Lung Cancer Congress 2022 as a poster.


Competing Interests

The authors have no relevant financial or nonfinancial interests to disclose.


Authors' Contributions

U.B. contributed to the study conception and design. Material preparation, data collection and analysis were performed by U.B., S.N., M.S., A.B.P., S.D., D.K., A.M., and S.V. The first draft of the manuscript was written by S.N. and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. The supervision for the entire study was by U.B.


Data Availability

The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.


Ethics Approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Rajiv Gandhi Cancer Institute and Research Center (RGCIRC/IRB-BHR/165/2021).




Publication History

Received: 05 July 2023

Accepted: 16 April 2024

Article published online:
29 May 2024

© 2024. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Solomon BJ, Mok T, Kim DW. et al; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371 (23) 2167-2177
    CrossrefPubMedGoogle Scholar
  • 2 Koopman B, Groen HJM, Schuuring E. et al. Actionability of on-target ALK resistance mutations in patients with non-small cell lung cancer: local experience and review of the literature. Clin Lung Cancer 2022; 23 (02) e104-e115
    CrossrefPubMedGoogle Scholar
  • 3 Choi YL, Soda M, Yamashita Y. et al; ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363 (18) 1734-1739
    CrossrefPubMedGoogle Scholar
  • 4 Accessed January 27, 2023 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf
  • 5 Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov 2017; 7 (02) 137-155
    CrossrefPubMedGoogle Scholar
  • 6 Gainor JF, Dardaei L, Yoda S. et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 2016; 6 (10) 1118-1133
    CrossrefPubMedGoogle Scholar
  • 7 Bhattacharyya GS, Agarwala V, MV C. ALK inhibitors fuel ALK resistance mutation: precision medicine takes on drug resistance. Cancer Res Stat Treat 2020; 3 (02) 405-406
    CrossrefGoogle Scholar
  • 8 Dagogo-Jack I, Shaw AT. Crizotinib resistance: implications for therapeutic strategies. Ann Oncol 2016; 27 Suppl 3 (Suppl. 03) iii42-iii50
    CrossrefPubMedGoogle Scholar
  • 9 Dagogo-Jack I, Yoda S, Lennerz JK. et al. MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Clin Cancer Res 2020; 26 (11) 2535-2545
    CrossrefPubMedGoogle Scholar
  • 10 Kim HR, Kim WS, Choi YJ, Choi CM, Rho JK, Lee JC. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. Mol Oncol 2013; 7 (06) 1093-1102
    CrossrefPubMedGoogle Scholar
  • 11 Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012; 17 (11) 1351-1375
    CrossrefPubMedGoogle Scholar
  • 12 Blackhall F, Ross Camidge D, Shaw AT. et al. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO Open 2017; 2 (03) e000219
    CrossrefPubMedGoogle Scholar
  • 13 Tabbò F, Reale ML, Bironzo P, Scagliotti GV. Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won. Transl Lung Cancer Res 2020; 9 (06) 2545-2556
    CrossrefPubMedGoogle Scholar
  • 14 Pan Y, Deng C, Qiu Z, Cao C, Wu F. The resistance mechanisms and treatment strategies for ALK-rearranged non-small cell lung cancer. Front Oncol 2021; 11: 713530
    CrossrefPubMedGoogle Scholar
  • 15 McCoach CE, Blakely CM, Banks KC. et al. Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer. Clin Cancer Res 2018; 24 (12) 2758-2770
    CrossrefPubMedGoogle Scholar
  • 16 Batra U, Sharma M, Joga S, Jain P. First-line treatment of EGFR-mutant NSCLC: spoiled for choice?. Cancer Res Stat Treat 2019; 2 (02) 251-252
    CrossrefGoogle Scholar
  • 17 Camidge DR, Dziadziuszko R, Peters S. et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol 2019; 14 (07) 1233-1243
    CrossrefPubMedGoogle Scholar
  • 18 Lin JJ, Zhu VW, Yoda S. et al. Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer. J Clin Oncol 2018; 36 (12) 1199-1206
    CrossrefPubMedGoogle Scholar
  • 19 Yoda S, Lin JJ, Lawrence MS. et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov 2018; 8 (06) 714-729
    CrossrefPubMedGoogle Scholar
  • 20 Cognigni V, Pecci F, Lupi A. et al. The landscape of ALK-rearranged non-small cell lung cancer: a comprehensive review of clinicopathologic, genomic characteristics, and therapeutic perspectives. Cancers (Basel) 2022; 14 (19) 4765
    CrossrefPubMedGoogle Scholar
  • 21 Cho BC, Kim DW, Bearz A. et al. ASCEND-8: a randomized phase 1 study of ceritinib, 450.  mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol 2017; 12 (09) 1357-1367
    CrossrefPubMedGoogle Scholar
  • 22 Rolfo C, Mack P, Scagliotti GV. et al. Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer. J Thorac Oncol 2021; 16 (10) 1647-1662
    CrossrefPubMedGoogle Scholar
  • 23 El-Sayes N, Vito A, Mossman K. Tumor heterogeneity: a great barrier in the age of cancer immunotherapy. Cancers (Basel) 2021; 13 (04) 806
    CrossrefPubMedGoogle Scholar
  • 24 Malapelle U, Pisapia P, Pepe F. et al. The evolving role of liquid biopsy in lung cancer. Lung Cancer 2022; 172: 53-64
    CrossrefPubMedGoogle Scholar
  • 25 Yoshida R, Sasaki T, Umekage Y. et al. Highly sensitive detection of ALK resistance mutations in plasma using droplet digital PCR. BMC Cancer 2018; 18 (01) 1136
    CrossrefPubMedGoogle Scholar
  • 26 Kim S, Kim TM, Kim D-W. et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol 2013; 8 (04) 415-422
    CrossrefPubMedGoogle Scholar
  • 27 Takeuchi K, Togashi Y, Kamihara Y. et al. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol 2016; 27 (01) 185-192
    CrossrefPubMedGoogle Scholar
  • 28 Shaw AT, Solomon BJ, Besse B. et al. ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. J Clin Oncol 2019; 37 (16) 1370-1379
    CrossrefPubMedGoogle Scholar
  • 29 Okada K, Araki M, Sakashita T. et al. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. EBioMedicine 2019; 41: 105-119
    CrossrefPubMedGoogle Scholar
  • 30 Lu Y, Fan Z, Zhu SJ. et al. A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC. EMBO Mol Med 2022; 14 (01) e14296
    CrossrefPubMedGoogle Scholar